KR20240021774A - Idh 돌연변이 억제제 및 이의 용도 - Google Patents

Idh 돌연변이 억제제 및 이의 용도 Download PDF

Info

Publication number
KR20240021774A
KR20240021774A KR1020237041032A KR20237041032A KR20240021774A KR 20240021774 A KR20240021774 A KR 20240021774A KR 1020237041032 A KR1020237041032 A KR 1020237041032A KR 20237041032 A KR20237041032 A KR 20237041032A KR 20240021774 A KR20240021774 A KR 20240021774A
Authority
KR
South Korea
Prior art keywords
compound
compounds
pharmaceutically acceptable
formula
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041032A
Other languages
English (en)
Korean (ko)
Inventor
유리 시에
후씽 판
리후이 취앤
Original Assignee
위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 filed Critical 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드
Publication of KR20240021774A publication Critical patent/KR20240021774A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237041032A 2021-06-15 2022-06-15 Idh 돌연변이 억제제 및 이의 용도 Pending KR20240021774A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110661394.5 2021-06-15
CN202110661394 2021-06-15
PCT/CN2022/099018 WO2022262784A1 (zh) 2021-06-15 2022-06-15 Idh突变体抑制剂及其用途

Publications (1)

Publication Number Publication Date
KR20240021774A true KR20240021774A (ko) 2024-02-19

Family

ID=84526875

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041032A Pending KR20240021774A (ko) 2021-06-15 2022-06-15 Idh 돌연변이 억제제 및 이의 용도

Country Status (10)

Country Link
US (1) US20240208978A1 (cg-RX-API-DMAC7.html)
EP (1) EP4356914A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884019B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240021774A (cg-RX-API-DMAC7.html)
CN (1) CN117460512A (cg-RX-API-DMAC7.html)
AU (1) AU2022294860A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024454A2 (cg-RX-API-DMAC7.html)
CA (1) CA3217608A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013664A (cg-RX-API-DMAC7.html)
WO (1) WO2022262784A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026035776A1 (en) * 2024-08-05 2026-02-12 Frontier Medicines Corporation Pi3k-alpha binding compounds and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012184205A (ja) * 2011-03-08 2012-09-27 Dainippon Sumitomo Pharma Co Ltd 2−アミノ置換8−オキソジヒドロプリン誘導体
SMT202200255T1 (it) * 2012-09-28 2022-07-21 Takeda Pharmaceuticals Co Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea
CA2903979A1 (en) * 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
MA46064B1 (fr) * 2014-09-19 2020-04-30 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
US9624175B2 (en) * 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2017019429A1 (en) 2015-07-27 2017-02-02 Eli Lilly And Company 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors
JP6682043B2 (ja) 2016-06-06 2020-04-15 イーライ リリー アンド カンパニー 変異体idh1阻害剤
CN107556366B (zh) * 2016-06-30 2025-02-07 上海海和药物研究开发股份有限公司 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途
KR102232614B1 (ko) * 2016-07-21 2021-03-29 난징 산홈 팔마세우티칼 컴퍼니 리미티드 이소시트레이트 탈수소효소 억제제의 화학적 화합물 및 이의 적용
JP6793836B2 (ja) * 2016-12-16 2020-12-02 イーライ リリー アンド カンパニー 変異体idh1およびidh2阻害剤としての7−フェニルエチルアミノ−4h−ピリミド[4,5−d][1,3]オキサジン−2−オン化合物
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
WO2020141439A1 (en) * 2018-12-31 2020-07-09 Integral Biosciences Private Limited Heterocyclic compounds as mutant idh inhibitors

Also Published As

Publication number Publication date
EP4356914A1 (en) 2024-04-24
CA3217608A1 (en) 2022-12-22
BR112023024454A2 (pt) 2024-02-06
AU2022294860A1 (en) 2024-01-25
MX2023013664A (es) 2024-01-08
EP4356914A4 (en) 2025-01-08
US20240208978A1 (en) 2024-06-27
JP7884019B2 (ja) 2026-07-02
JP2024524933A (ja) 2024-07-09
WO2022262784A1 (zh) 2022-12-22
CN117460512A (zh) 2024-01-26

Similar Documents

Publication Publication Date Title
JP7773987B2 (ja) スピロ環含有キナゾリン化合物
JP7850663B2 (ja) スピロ環含有キナゾリン化合物
CN113767103B (zh) 新型螺环类K-Ras G12C抑制剂
EP4328224A1 (en) Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
CN115315427B (zh) Hpk1抑制剂及其制备方法和用途
EP4365170A1 (en) Amide compound and use thereof
CN118027016A (zh) Parg抑制剂及其制备方法和用途
EP3354647B1 (en) Egfr kinase inhibitor and preparation method and use thereof
US20230126480A1 (en) Benzo 2-azaspiro[4.4]nonane compound and use thereof
EP4356914A1 (en) Idh mutant inhibitor and use thereof
RU2860311C2 (ru) Ингибитор мутанта idh и его применение
EP4741391A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
CN113880804A (zh) 新型苯并咪唑化合物
JP7777544B2 (ja) 新規ピラジン化合物
CN115768775B (zh) Idh突变体抑制剂及其用途
CN118139846A (zh) 一种egfr小分子抑制剂、含其的药物组合物及其用途
RU2857202C2 (ru) Ингибитор parp, содержащий пиперазиновую структуру, способ его получения и фармацевтическое применение
US12577250B2 (en) 1,2,4-triazolone derivative as DHODH inhibitor, and preparation method therefor and use thereof
EP4488263A2 (en) Phenylurea derivative and pharmaceutical use thereof
JP2025540298A (ja) Hdac阻害剤およびその使用
CA3285927A1 (en) Kif18a inhibitor
JP2025534771A (ja) Tyk2阻害剤としての複素環式化合物及び合成及び応用
CN116249702A (zh) 用作dhodh抑制剂的1,2,4-三唑酮衍生物
US20080299218A1 (en) Deuterium-enriched valsartan

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902